Siamab’s Antibody-drug Conjugates for Ovarian Cancer Seen to Succeed in Animal Models

Siamab’s Antibody-drug Conjugates for Ovarian Cancer Seen to Succeed in Animal Models
Siamab Therapeutics’ preclinical work with anti-STn antibody-drug conjugates is moving forward, and in animal models — including primates — it showed the conjugates could safely and effectively treat ovarian cancer resistant to chemotherapy. The treatment blocked tumor progression in all models tested, in which scientists injected patient-derived or lab-grown ovarian cancer cells into mice. Researchers

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Tagged , , , , , .

Magdalena holds an MSc in Pharmaceutical Bioscience and an interdisciplinary PhD merging the fields of psychiatry, immunology and neuropharmacology. Her previous research focused on metabolic and immunologic changes in psychotic disorders. She is now focusing on science writing, allowing her to culture her passion for medical science and human health.

Leave a Comment

Your email address will not be published. Required fields are marked *